Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination

Sanders, A ORCID:, Owen, S, Morgan, L D ORCID:, Ruge, F, Collins, R, Ye, L ORCID:, Mason, M ORCID: and Jiang, W G ORCID: 2019. Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination. Oncotarget 10 (59) , pp. 6362-6377. 10.18632/oncotarget.27279

[thumbnail of Sanders et al ALCAM Oncotarget 27279-1041695-1-PB, 2019 reprint.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (5MB) | Preview


Activated Leukocyte Cell Adhesion Molecule (ALCAM) has been linked to the progression of numerous human cancers, where it appears to play a complex role. The current study aims to further assess the importance of ALCAM in prostate cancer and the prognostic potential of serum ALCAM as a biomarker for prostate cancer progression. Here we demonstrate enhanced levels of tissue ALCAM are associated with metastasis. Additionally, elevated serum ALCAM is indicative of progression and poorer patient outlook, and demonstrates comparable prognostic ability to PSA in terms of metastasis and prostate cancer survival. ALCAM suppression enhanced proliferation and invasiveness in PC-3 cells and motility/migration in PC-3 and LNCaP cells. ALCAM suppressed PC-3 cells were generally less responsive to HGF and displayed reduced MET transcript expression. Furthermore a recombinant human ALCAM-Fc chimera was able to inhibit LNCaP cell attachment to HECV and hFOB1.19 cells. Taken together, ALCAM appears to be a promising biomarker for prostate cancer progression, with enhanced serum expression associated with poorer prognosis. Suppression of ALCAM appears to impact cell function and cellular responsiveness to certain micro environmental factors.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Impact Journals
ISSN: 1949-2553
Funders: Cancer Research Wales
Date of First Compliant Deposit: 5 November 2019
Date of Acceptance: 5 September 2019
Last Modified: 23 Feb 2024 03:44

Citation Data

Cited 13 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics